Danaher Corporation (NYSE:DHR) is a global science and technology innovator, operating in sectors like Life Sciences, Diagnostics, and Biotechnology. On January 28, 2026, Evercore ISI maintained its "Outperform" rating for Danaher, with the stock priced at $223.92. The firm also raised its price target from $250 to $254, indicating confidence in Danaher's future performance.
Danaher's recent financial results support Evercore ISI's positive outlook. The company reported fourth-quarter adjusted earnings per share (EPS) of $2.23, slightly above the Zacks Consensus Estimate of $2.22. Net sales reached $6.84 billion, surpassing expectations of $6.79 billion, marking a 4.5% increase from the previous year. This growth was driven by strong performances in its key segments.
The Biotechnology segment saw a revenue surge of 9%, while Diagnostics profits rose by 14.3%. For the full year 2025, Danaher achieved net revenues of $24.6 billion, reflecting a 3% year-over-year increase. The company projects low single-digit core sales growth in the first quarter of 2026, with adjusted EPS expected to range from $8.35 to $8.50.
Despite these positive results, Danaher's stock is currently priced at $223.995, reflecting a decrease of approximately 4.99% with a change of -$11.75. The stock has fluctuated between a low of $223.09 and a high of $235.07 today. Over the past year, it reached a high of $242.8 and a low of $171, with a market capitalization of approximately $160.39 billion.
Foreign-currency translations positively impacted the quarter's results by 2.5%, although acquisitions and divestitures had a slight negative effect of 0.5%. The trading volume for the day is 5,105,026 shares on the NYSE, indicating active investor interest. Danaher's strong financial performance and strategic outlook continue to make it a compelling investment choice.
